Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era
Neal S. McCall, Hamilton S. McGinnis, James Janopaul‐Naylor, Aparna H. Kesarwala, Sibo Tian, William A. Stokes, Joseph W. Shelton, Conor Steuer, Jennifer W. Carlisle, Ticiana Leal, Suresh S. Ramalingam, Jeffrey D. Bradley, Kristin Higgins
Topics & Concepts
DurvalumabMedicineInternal medicineLung cancerOncologyHazard ratioGastroenterologyRadiation therapyProportional hazards modelStage (stratigraphy)CancerImmunotherapyConfidence intervalBiologyPembrolizumabPaleontologyCancer Immunotherapy and BiomarkersEffects of Radiation ExposureLung Cancer Diagnosis and Treatment